Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a ...

Semaglutide is the active ingredient in certain brand-name medications prescribed for obesity, type 2 diabetes, and more. Semaglutide belongs to the glucagon-like peptide-1 (GLP-1) receptor ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Semaglutide was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 ...

If you continue to have this issue please contact [email protected]. Semaglutide was tied to nonarteritic anterior ischemic optic neuropathy (NAION) risk vs. nonuse in adults with type ...

The FBI says counterfeit versions of the drugs can cause health issues. The FBI is warning the public about counterfeit compounded weight loss drugs on the market that claim to contain semaglutide ...

A study by Mass General Brigham found that taking the weight-loss drug semaglutide before bariatric surgery does not lead to better overall weight loss outcomes. The research suggests that ...

Tirzepatide and lifestyle modification generated 48,649 life-years gained per 100,000 eligible individuals, and semaglutide and lifestyle modification generated 35,634 life-years gained per ...

Semaglutide supports weight loss in MASLD/MASH for all diabetes groups The medication shows consistent effectiveness across groups, with no major differences in weight loss By reducing weight and ...

Compounders are on alert after the US Food and Drug Administration (FDA) declared the shortage of semaglutide –the active ingredient in glucagon-like peptide 1 receptor agonist (GLP-1RA ...

What Happens If I Use Expired Semaglutide? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the type 2 diabetes and weight loss medication sold under the brand ...

The Food and Drug Administration (FDA) on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, is no longer in short supply. The FDA's move is bad news ...

Researchers found that among semaglutide users, the incidence rate of nonarteritic anterior ischemic optic neuropathy was 14.5 per 100,000 person-years. HealthDay News — For individuals with ...